Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com
Equities researchers at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report released on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the company. Oppenheimer restated a “market perform” rating on shares of Cellectar Biosciences […]
Equities researchers at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report released on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the company. Oppenheimer restated a “market perform” rating on shares of Cellectar Biosciences […]
